ReviewThe Korean journal of internal medicine2022

Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.

Soo-Young Na et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.